Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Paychex, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Paychex, Inc. trades at $109.38 (market cap $37.82B). The key difference: Paychex, Inc. is far larger — about 13.2× Dyne Therapeutics Inc. Common Stock's market cap, and Paychex, Inc. pays a 4.48% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Paychex, Inc. for 56 Days on average.
| DYN | PAYX | |
|---|---|---|
Market Cap | $2.86B | $37.82B |
Volume | 3,341,579 | 2,018,238 |
Sector | Health | Industrials |
52-Week High | $26.78 | $127.54 |
52-Week Low | $14.60 | $85.57 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $2.18B | $41.51B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Paychex (PAYX) trades at $108.37, up 3.56% today, with mixed technical signals showing bullish overall momentum but bearish moving averages. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.34 beating $1.32 estimates, and robust profitability metrics including 27.35% net income margin and 47.06% ROE. Recent news highlights dividend safety concerns despite the company's 5-star rating on Newsweek's America's Greatest Companies 2026 list.
Outlook remains cautiously optimistic with analyst consensus target of $111 suggesting modest upside, though high valuation multiples (P/E 21.08, P/S 5.77) and competitive pressures in payroll services present risks. The stock offers income potential with recent $1.19 dividend, but investors should monitor PEO segment performance and labor market trends affecting small business clients.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
